Director Eric D. Shaff of Seres Therapeutics, Inc. filed a Form 4 on November 17, 2026, disclosing the vesting of restricted stock units and a sale of common stock on November 15 and 16, 2026, under a pre-established Rule 10b5-1 plan.
Key Highlights
- RSU Vesting: Shaff acquired 724 shares of common stock on November 15, 2026, through the settlement of restricted stock units, at no cost.
- Tax-Cover Sale: Shaff disposed of 287 shares on November 16, 2026, at $1.38 per share, solely to cover taxes related to the RSU vesting, according to the filing.
- Resulting Ownership: Following both transactions, Shaff directly held 12,936 shares of common stock.
- 10b5-1 Plan: The sale was effected pursuant to a Rule 10b5-1 instruction adopted by Shaff on March 2, 2023.
- Remaining RSUs: After the vesting transactions, Shaff held 392 and 1,660 restricted stock units from two separate RSU grants, respectively.
- Issuer: Seres Therapeutics, Inc. trades on NASDAQ:MCRB.
Eric D. Shaff RSU Vesting and Share Sale at Seres Therapeutics
According to the Form 4 filed on November 17, 2026, Eric D. Shaff, a director of Seres Therapeutics, Inc. (NASDAQ:MCRB), reported two related transactions spanning November 15 and 16, 2026. On November 15, Shaff acquired 724 shares of common stock through the settlement of restricted stock units, bringing his directly held common stock to 13,223 shares before the subsequent sale.
On November 16, 2026, Shaff disposed of 287 shares at a price of $1.38 per share. The filing states that "the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units." Following this sale, Shaff's direct beneficial ownership of common stock stood at 12,936 shares.
The November 15 vesting comprised shares from two separate RSU grants. Under the first grant, 391 restricted stock units settled on that date; that grant originally vested 25% on February 15, 2024, with the remainder vesting and settling in 12 equal quarterly installments thereafter, and carries no expiration date. Under the second grant, 333 restricted stock units settled on November 15, 2026; that grant originally vested 25% on February 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, also with no expiration date. After these transactions, Shaff held 392 and 1,660 restricted stock units remaining from the respective grants. The filing notes that each restricted stock unit represents a contingent right to receive one share of issuer common stock, and both grants settled at $0 exercise price.
What Was Disclosed
The filing disclosed RSU-driven acquisition of 724 shares and a 287-share tax-cover sale at $1.38 by director Eric D. Shaff on November 15 and 16, 2026, under a 10b5-1 plan, leaving him with 12,936 directly held shares.



Please wait processing your request...